抗体靶向治疗药 ppt课件.pptVIP

FDA 批准用于治疗肿瘤的抗体药物 Rituxan (1997): 非霍奇金B 细胞淋巴瘤 Herceptin (1998): 乳腺癌 Mylotarg (2000): 复发的急性髓细胞性白血病 Campath-1H (2001): 难治的慢性淋巴细胞白血病 Zevalin (2002): 难治的非霍奇金B 细胞淋巴瘤 Bexxar (2003): 难治的非霍奇金B 细胞淋巴瘤 Erbitux (2004): 结肠直肠癌 Avastin (2004): 结肠直肠癌 Vectibix (2006): 结肠直肠癌 单克隆抗体肿瘤靶向治疗 bind to antigens present preferentially or exclusively on tumor cells. Zevalin Bexxar Mylotarg 单克隆抗体作为肿瘤治疗的体内应用策略 Antibody Alone Complement mediated cytotoxicity (CMC) Antibody dependent cell-mediated cytotoxicity (ADCC) Regulatory (ligand/receptor) interactions Anti-idiotype vaccine Immunoconjugates Radiolabeled Antibodies Immunotoxins Chemotherapy-Antibody Conjugates Cytokine Immunoconjugates Cellular Immunoconjugates Antibody fragments in clinical and preclinical development Antibody fragments in clinical and preclinical development Therapeutic mAbs currently in phase 3 studies CTLA, cytotoxic T-lymphocyte associated protein; EGF, epidermal growth factor; MRSA, methicillin-resistant Staphylococcus aureus; RANKL, receptor for activation of nuclear factor-κB ligand; RSV, respiratory syncytial virus; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. 近几年处在临床实验中的免疫毒素 AAPS J 2006 近几年处在临床实验中的免疫毒素 AAPS J 2006 Schematic representation of immunoglobulin fragments Fab scFv diabody dAb (VH or VL) Possible different configurations of fusion proteins of cytokines with either full-length antibody molecules or the antigen-binding sites (scFv) are depicted. The cytokine or chemokine moiety has been fused at the N- or C-terminal of the heavy chain [(a) and (b)], or at the N-terminal end (c) or C-terminal end of the scFv (d) or both (e). In addition, fusion proteins of two cytokines have also been described. Immunocytokines and their configurations * 1 * 1 * 1 * 1 * 1 抗体靶向治疗药物 邵荣光，甄永苏： 抗体靶向治疗药物 见：王晓良主编. 应用分子药理学. 中国协和医科大学出版社，北京，2005 甄永苏，邵荣光主编： 抗体工程药物 化学工业出版社，北京，2002 LYMPHOCYTE HYBRIDO